top of page


MAIA Biotechnology Awarded $2.3 Million Grant by National Institutes of Health for THIO-101 Phase 2 Trial of Cancer-Fighting Agent
THIO-101 Phase 2 trial to enroll patients in the U.S. as part of the expansion of the study in third-line treatment for advanced...


Armstrong Asia Signs MOU with Checkmate Capital Group to Explore Strategic Collaboration
SINGAPORE, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Armstrong Asia, a leading Singapore-based manufacturer of flexible material solutions with...


MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies
Agreement to support future studies investigating the combination of ateganosine and atezolizumab for safe and effective cancer...
Press
bottom of page